Drug Discovery
NanoViricides Highlights Broad-Spectrum Antiviral Candidate After Andes Hantavirus Incident on Cruise Ship
NanoViricides points to its clinical-stage antiviral candidate NV-387 as a potential broad-spectrum therapeutic following an Andes hantavirus incident aboard a cruise ship, underscoring the need for versatile antiviral treatments.
Silo Pharma Launches Ibogaine-Based TBI Therapeutics Initiative
Silo Pharma announced a strategic initiative to develop ibogaine-based therapeutics for traumatic brain injury and related conditions, filing a provisional patent application.
Blocking Fructose Metabolism Shows Promise Against Pediatric Brain Cancer
New research from Johns Hopkins reveals that disrupting fructose metabolism in tumor cells could slow group 3 medulloblastoma, a deadly childhood brain cancer, offering a potential new treatment avenue.
Lantern Pharma Expands predictBBB Platform into Large Quantitative Model for Drug Discovery
Lantern Pharma announced the expansion of its predictBBB platform into a Large Quantitative Model (LQM), enabling real-time molecular intelligence for drug discovery, which could accelerate development and reduce costs.
Oncotelic's PDAOAI Platform Targets AI Bias in Pharma with Evidence-Interrogation Approach
Oncotelic Therapeutics' PDAOAI platform indexes over 125,000 PubMed abstracts on TGF-β signaling to generate testable hypotheses, addressing transparency and bias challenges in AI-driven drug discovery.
LIXTE Biotechnology Advances Precision Oncology with Novel PP2A Inhibitor LB-100
LIXTE Biotechnology Holdings is developing LB-100, a first-in-class PP2A inhibitor that enhances chemotherapy and immunotherapy while reducing side effects, with ongoing clinical trials for ovarian and colon cancers.
Lantern Pharma to Showcase AI Co-Scientist Platform withZeta.ai in Live Public Demo
Lantern Pharma will host its first live demonstration of the withZeta.ai AI co-scientist platform on April 30, 2026, showcasing its ability to accelerate oncology drug discovery and marking a potential new revenue stream through a subscription model.
SureNano Science Advances GLP-1 Drug Candidate Toward Clinical Trials, Expands Investor Outreach
SureNano Science Ltd. is moving its lead obesity and diabetes drug GEP-44 into FDA IND-enabling studies with LabCorp while broadening investor communications through a partnership with Investor Brand Network.
Oncotelic Therapeutics Featured in BioMedWire Editorial on Biotech Valuation Shift
Oncotelic Therapeutics' inclusion in a BioMedWire editorial highlights how advancing drug pipelines are reshaping biotech valuations, with its AI-driven oncology pipeline and 45% stake in GMP Bio serving as examples of innovation translating into tangible enterprise value.
LIXTE Biotechnology's LB-100 Represents Novel Cancer Treatment Approach Through PP2A Inhibition
LIXTE Biotechnology Holdings is advancing LB-100, a first-in-class PP2A inhibitor designed to enhance existing cancer therapies by making tumors more responsive to chemotherapy and immunotherapy in multiple clinical programs targeting solid tumors with significant unmet medical need.
Lantern Pharma Reports Strong Q3 2025 Results with AI-Driven Oncology Pipeline Advances
Lantern Pharma demonstrated significant clinical progress in its AI-driven oncology programs, including successful Phase 1a trial results for LP-184 and regulatory clarity for pediatric CNS cancer development, positioning the company to address multiple high-value cancer markets.
Oragenics Regains NYSE Compliance While Advancing Neurological Therapeutics Pipeline
Oragenics Inc. has regained full NYSE American compliance while making significant progress toward its first clinical trial and expanding its neurological therapeutics pipeline through an AI-driven collaboration with Receptor.AI.
Lantern Pharma to Host Q3 2025 Results Webcast, Highlighting AI-Driven Oncology Pipeline
Lantern Pharma will review its third-quarter 2025 financial results and AI platform developments during a November webcast, showcasing how artificial intelligence is accelerating cancer drug discovery and development.
NanoViricides Sets 2025 Annual Shareholders Meeting Amid Clinical Development Push
NanoViricides announced its 2025 shareholders meeting while advancing multiple antiviral drug candidates including NV-387 for respiratory infections and NV-HHV-1 for shingles treatment.
Pacylex and Heidelberg Pharma Present Promising Zelenirstat ADC Data at World ADC Conference
Pacylex Pharmaceuticals and Heidelberg Pharma are presenting data showing zelenirstat's potential as a novel antibody drug conjugate payload, demonstrating significantly increased potency against breast and prostate cancer cells compared to oral administration alone.
NanoViricides to Present Broad-Spectrum Antiviral Pipeline at Spartan Capital Investor Conference
NanoViricides will present its clinical-stage antiviral drug pipeline at the Spartan Capital Investor Conference, highlighting the potential significance of its platform technology for treating multiple viral diseases including RSV, COVID-19, influenza, and other respiratory infections.
Lifordi Immunotherapeutics Advances Glucocorticoid ADC LFD-200 into Phase 1 Rheumatoid Arthritis Trial Following Promising Nonclinical Data
Lifordi Immunotherapeutics has initiated Phase 1 clinical trials for LFD-200, a novel antibody-drug conjugate that delivers glucocorticoids directly to immune cells, potentially overcoming the systemic toxicity limitations that have restricted steroid use in autoimmune diseases for decades.
Lantern Pharma Reports Complete Response in AI-Driven Cancer Drug Trial
Lantern Pharma's AI-developed drug LP-284 achieved a complete metabolic response in a heavily pre-treated lymphoma patient, demonstrating the potential of artificial intelligence to accelerate oncology drug development and address critical treatment gaps.
Oncotelic Therapeutics Fills Critical Gaps in Cancer Treatment with RNA and Small-Molecule Therapies
Oncotelic Therapeutics is developing innovative RNA therapeutics and small-molecule drugs to address unmet needs in rare pediatric cancers and resistant solid tumors where traditional treatments have fallen short.
Lantern Pharma Advances Rare Pediatric Brain Cancer Treatment Using AI Platform
Lantern Pharma is preparing clinical trials for a rare pediatric brain cancer treatment using its AI-powered RADR platform, following positive FDA feedback on trial design and regulatory pathways.
University of Utah Enzyme Discovery Enables Programmable Peptide Modifications for Next-Generation Diabetes and Obesity Treatments
University of Utah researchers have developed an enzyme technology that can stabilize and enhance therapeutic peptides for diabetes and obesity treatments, with the innovation now advancing toward clinical development through spinout company Sethera Therapeutics.
Lifordi Immunotherapeutics Reports Promising Preclinical Data for Autoimmune Treatment LFD-200
Lifordi Immunotherapeutics will present new preclinical data showing its antibody drug conjugate LFD-200 delivers glucocorticoids directly to immune cells with sustained anti-inflammatory effects and no systemic toxicity, potentially offering a safer treatment option for autoimmune diseases.
Oragenics Partners with Receptor.AI to Accelerate AI-Driven Discovery of Brain-Targeted Therapeutics
Oragenics Inc. has formed a strategic collaboration with Receptor.AI to leverage artificial intelligence for developing neurological therapeutics, marking a significant expansion beyond its concussion treatment program.
Quantum BioPharma Advances Multiple Sclerosis Treatment Toward Clinical Trials
Quantum BioPharma has received final toxicity reports for its Lucid-MS drug candidate, clearing a critical regulatory hurdle toward Phase 2 clinical trials for treating multiple sclerosis by targeting demyelination.
Creative Biolabs Launches Advanced Antibody Tools for Neuroscience Research
Creative Biolabs has developed specialized antibody products targeting key neurological proteins that could accelerate research into neurodegenerative diseases, movement disorders, and synaptic function.
Insilico Medicine CEO Outlines Path to Pharmaceutical Superintelligence as AI-Discovered Drugs Advance Through Clinical Trials
Insilico Medicine's CEO details how generative AI is transforming drug discovery, compressing development timelines and advancing multiple clinical programs, with the first fully AI-designed drugs potentially reaching patients within five to six years.
Creative Biolabs Launches Advanced Neuroscience Platforms to Address Growing Neurodegenerative Disease Research Needs
Creative Biolabs has introduced specialized neuroscience research platforms targeting Alzheimer's and other neurodegenerative diseases, providing critical tools for studying cellular mechanisms in both peripheral and central nervous systems to accelerate drug development and mechanistic studies.
Lantern Pharma Completes Successful Phase 1a Trial for AI-Driven Cancer Drug LP-184
Lantern Pharma's AI-developed oncology drug LP-184 demonstrates promising safety and efficacy in Phase 1a trial, showing disease control in 48% of evaluable patients with advanced solid tumors and paving the way for targeted cancer treatments.
Clene's CNM-Au8 Shows Promise in Parkinson's Disease Preclinical Study
Clene Inc. presented preclinical data demonstrating its investigational drug CNM-Au8 improves mitochondrial function and reduces inflammation in Parkinson's disease models, potentially offering a new neuroprotective treatment approach.
New Research Identifies SOX6 Protein as Potential Key to Myelin Repair in Multiple Sclerosis
Groundbreaking research published in Cell reveals that targeting the SOX6 protein could enable myelin repair in multiple sclerosis patients, potentially opening new therapeutic avenues for the neurodegenerative disease.